Skip to main content

Vyscoxa Dosage

Generic name: CELECOXIB 10mg in 1mL
Dosage form: oral suspension
Drug class: Cox-2 inhibitors

Medically reviewed by Drugs.com. Last updated on Jul 31, 2025.

General Dosing Instructions

Carefully consider the potential benefits and risks of VYSCOXA and other treatment options before deciding to use VYSCOXA. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.

The maximum single dose of VYSCOXA is 200 mg (20 mL). Administering more than 200 mg (20 mL) in a single dose of the VYXCOXA suspension may result in higher than intended plasma concentrations of celecoxib. In patients requiring a single dose greater than 200 mg (20 mL), use a different product.

VYSCOXA must be taken on an empty stomach at least 2 hours before or 1 hour after food.

For patients who cannot tolerate dosing with VYSCOXA on an empty stomach, discontinue the use of this product. Do not advise the patient to take VYSCOXA with food.

Osteoarthritis

For OA, the dosage is 200 mg (20 mL) per day administered as a single dose or as 100 mg (10 mL) twice daily.

Rheumatoid Arthritis

For RA, the dosage is 100 mg (10 mL) to 200 mg (20 mL) twice daily.

Ankylosing Spondylitis

For AS, the dosage is 200 mg (20 mL) daily in single (once per day) dose or 100 mg (10 mL) twice daily. If no effect is observed after 6 weeks, a trial of 200 mg (20 mL) twice daily may be worthwhile. If no effect is observed after 6 weeks on 200 mg (20 mL) twice daily, a response is not likely and consideration should be given to alternate treatment options.

Juvenile Rheumatoid Arthritis

For JRA, the dosage for pediatric patients (age 2 years and older) is based on weight. For patients weighing 10 kg to 25 kg the recommended dose is 50 mg (5 mL) twice daily. For patients greater than 25 kg the recommended dose is 100 mg (10 mL) twice daily.

Special Populations

Hepatic Impairment

In patients with moderate hepatic impairment (Child-Pugh Class B), reduce the dose by 50%. The use of VYSCOXA in patients with severe hepatic impairment is not recommended.

Poor Metabolizers of CYP2C9 Substrates

In adult patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin), initiate treatment with half of the lowest recommended dose.

In patients with JRA who are known or suspected to be poor CYP2C9 metabolizers, consider using alternative treatments.

Does Vyscoxa interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Frequently asked questions

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.